More NCEs added to Japan's NHI reimbursement list late December
Nine active ingredients covering 16 new products were added to Japan's National Health Insurance drug reimbursement price list on December 14, 2007.
Among the New Chemical Entities was Japanese pharmaceutical major Chugai's Tarceva (erlotinib), an endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of inoperable and recurrent/progressive non-small cell lung cancer. The NHI drug prices for the 25mg, 100mg and 150mg tablet formulations were set at 1,954.20 yen ($17.49), 7,183.90 yen and 10,513.00 yen, respectively. A "usefulness premium" of 5% was awarded to the product. Sales of the drug are expected to reach 400.0 million yen for the first year and its peak at 15.6 billion yen in its 10th year.
Chugai to undertake PMS
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze